Amgen's Epogen headwinds increasing, says Goldman:Goldman said the favorable FDA panel recommendation for Affymax's (AFFY) Peginesatide increases headwinds for Amgen's (AMGN) Epogen and views it as another step towards lower Epogen sales and pricing. Shares are Sell rated with a $50 price target.
Pretty amazing that Goldman thinks enough to actually put a SELL on Amgen.Goldman is king of the hill, and their comments carry the most weight on Wall Street, and have for a long time. THIS STATEMENT IS HUGE as regards the market for our AFFY drug!!!!!!!
Goldman comments move the whole market, imagine what it will do to AFFY. They are connected, probably they recommend this stock to their customers.